SCHEMBL2282707

SCHEMBL2282707

COC(=O)COc1cccc(C=CC(=O)c2c(OCc3ccccc3)cc(C)n(C)c2=O)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.48
KDM4E B2RXH2 2/20 0.48
PKM P14618 1/20 0.48
MEN1 O00255 1/20 0.48
POLB P06746 1/20 0.48
KMT2A Q03164 1/20 0.48
BCHE P06276 2/20 0.47
PDE4A P27815 1/20 0.46
PDE4B Q07343 1/20 0.46
PDE4C Q08493 1/20 0.46
PDE4D Q08499 1/20 0.46
CYSLTR2 Q9NS75 2/20 0.44
CYSLTR1 Q9Y271 2/20 0.44
LMNA P02545 1/20 0.44
THRB P10828 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
HPGD P15428 2/20 0.41
SLC5A1 P13866 1/20 0.41
SLC5A2 P31639 1/20 0.41
ABCG2 Q9UNQ0 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2282703 1.00 ALDH1A1 (0.48) ALDH1A1KDM4EPKMMEN1POLB
SCHEMBL2279268 0.92 KDM4E (0.51) ALDH1A1KDM4EPKMMEN1POLB
SCHEMBL2279266 0.92 KDM4E (0.51) ALDH1A1KDM4EPKMMEN1POLB
SCHEMBL2283107 0.92 CYSLTR2 (0.46) ALDH1A1KDM4EBCHECYSLTR2CYSLTR1
SCHEMBL2283102 0.92 CYSLTR2 (0.46) ALDH1A1KDM4EBCHECYSLTR2CYSLTR1
SCHEMBL2277984 0.89 ABCG2 (0.49) MEN1POLBKMT2ABCHECYSLTR2
SCHEMBL2277980 0.89 ABCG2 (0.49) MEN1POLBKMT2ABCHECYSLTR2
SCHEMBL2274827 0.87 CYSLTR2 (0.42) ALDH1A1KDM4EMEN1POLBKMT2A
SCHEMBL2274821 0.87 CYSLTR2 (0.42) ALDH1A1KDM4EMEN1POLBKMT2A
SCHEMBL2283693 0.86 ALDH1A1 (0.47) ALDH1A1KDM4EMEN1KMT2ACYSLTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7989478-B2 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-08-02 US disclosed
US-20060211680-A1 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2006-09-21 US disclosed
EP-1671948-A1 CINNAMOYL COMPOUND AND USE OF THE SAME Sumitomo Chemical Company, Limited (JP) 2006-06-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211680-A1 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis COL2A1, COL1A1, COL14A1 ALDH1A1 576/4885KDM4E 2443/4885PKM 4691/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.